Cerecor Inc. (NASDAQ:CERC) Files An 8-K Other Events
Item 8.01.Other Events.
On December 5, 2016, Cerecor Inc. (the Company) issued a press
release in connection with the reporting of the results from its
Phase 2 clinical trial with CERC-501 for nicotine withdrawal. A
copy of the press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
|
Exhibit No. |
Description |
|
|
99.1 |
Press Release, dated December 5, 2016, entitled |
|
2
About Cerecor Inc. (NASDAQ:CERC)
Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT. Cerecor Inc. (NASDAQ:CERC) Recent Trading Information
Cerecor Inc. (NASDAQ:CERC) closed its last trading session down -0.24 at 1.75 with 425,558 shares trading hands.
